NORTHWEST BIO SHARED RESOURCE (NWBioSR) Northwest Bio Shared Resource (NWBioSR) provides patient consenting, human research biospecimen procurement, and annotation services. Patients are consented for (1) research use of biospecimens and electronic medical records-derived data and (2) enrollment in a registry of patients who consent to future contact for potential enrollment in clinical studies. All biospecimen and data handling is done under Institutional Review Board (IRB)-approved mechanisms. NWBioSR is organized under a Governance Committee with Consortium-wide representation and support. State-of-the-art information systems support operations, allowing broad Consortium access to: ? Registration of studies, associated IRB, and consent information ? Prospective identification of clinical samples, from which research biospecimens likely may be obtained, based on characteristics determined electronically prior to actual arrival of the clinical specimen in the hospital laboratory: 1. at the patient level, such as demographic information 2. at the visit level, such as tumor type and stage information 3. at the biospecimen level, such as aliquot stabilization time ? Procurement of research-only biospecimens, including blood draws obtained specifically for research and research-only biopsies ? Retrospective identification of clinical samples that pre-exist in the hospital laboratories and which may be used/subdivided for research (e.g., archival pathology blocks and slides as well as remnant blood ?leftover? in the laboratory medicine department from earlier clinical draws); ? Detailed annotation information including extensive extraction of medical records data as needed ? Generation of tissue microarrays as well as digital pathology image annotation and analysis of whole slide images ? Dissemination of biospecimen and annotation information through informatics efforts NWBioSR is a heavily-utilized facility, supporting a large number of clinical trials, translational research studies, Consortium biorepository collections, and external projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015704-46
Application #
10125959
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-01
Project End
2024-12-31
Budget Start
2021-01-01
Budget End
2021-12-31
Support Year
46
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
078200995
City
Seattle
State
WA
Country
United States
Zip Code
98109
Cheng, Heather H (2018) The resounding effect of DNA repair deficiency in prostate cancer. Urol Oncol 36:385-388
Poudel, Kumud R; Roh-Johnson, Minna; Su, Allen et al. (2018) Competition between TIAM1 and Membranes Balances Endophilin A3 Activity in Cancer Metastasis. Dev Cell 45:738-752.e6
Holly, Mayumi K; Smith, Jason G (2018) Adenovirus infection of human enteroids reveals interferon sensitivity and preferential infection of goblet cells. J Virol :
Eaton, Keith D; Romine, Perrin E; Goodman, Gary E et al. (2018) Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility. J Thorac Oncol 13:649-659
Bar, Merav; Flowers, Mary E D; Storer, Barry E et al. (2018) Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial. Biol Blood Marrow Transplant 24:308-313
Gauthier, Jordan; Turtle, Cameron J (2018) Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy. Curr Res Transl Med 66:50-52
Graves, Scott S; Parker, Maura H; Stone, Diane et al. (2018) Anti-Inducible Costimulator Monoclonal Antibody Treatment of Canine Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 24:50-54
Amundsen, Susan K; Smith, Gerald R (2018) The RecB helicase-nuclease tether mediates Chi hotspot control of RecBCD enzyme. Nucleic Acids Res :
Méndez, Eduardo; Rodriguez, Cristina P; Kao, Michael C et al. (2018) A Phase I Clinical Trial of AZD1775 in Combination with Neoadjuvant Weekly Docetaxel and Cisplatin before Definitive Therapy in Head and Neck Squamous Cell Carcinoma. Clin Cancer Res 24:2740-2748
Buckley, Sarah A; Percival, Mary-Elizabeth; Othus, Megan et al. (2018) A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study. Leuk Lymphoma :1-7

Showing the most recent 10 out of 1267 publications